Best Practices to Facilitate Innovation:

Medical Professional Societies

Dr. Allen S. Lichter
American Society of Clinical Oncology

Maintaining Public Trust

- 1. Council of Medical Specialty
 Societies (CMSS) Code of Conduct
- 2. Disclosure for our members



CODE FOR INTERACTIONS WITH COMPANIES

IV. Pr	inciples for Interaction9
1.	Independence9
2.	Transparency
3.	Accepting Charitable Contributions
4.	Accepting Corporate Sponsorships
5.	Society Meetings
6.	Awarding of Research Grants
7.	Clinical Practice Guidelines
8.	Society Journals
9.	Standards for Advertising
10.	Standards for Licensing

Posting 100% of our Support

Non-profit support:

The Breast Cancer Research Foundation	2013 - Young Investigator Award	\$120,000.00
The Breast Cancer Research Foundation	2013 - Long-term International Fellowship (LIFe)	\$130,000.00
The Breast Cancer Research Foundation	Evelyn H. Lauder Young Investigator Award Endowment Fund	\$1,300,000.00
The Cholangiocarcinoma Foundation	2013 - Young Investigator Award	\$60,000.00
The Community Foundation for Greater New Haven	General Mission Support	\$1,000.00
Community Foundation Greater Des Moines	Can cer Research	\$250.00
The Don Shula Foundation	2012 - Young Investigator Award	\$57,937.14
Doris Duke Charitable Foundation	2012-2013 Medical Student Rotation for Underrepresented Populations	\$40,000.00

Healthcare companies:

sanofi-aventis U.S.	2013 - Gastrointestinal Cancers Symposium	\$100,000.00
Seattle Genetics	2012 - Young Investigator Award	\$60,000.00
Seattle Genetics	2012 - Annual Meeting Patient Advocate Scholarship Program	\$10,000.00
Seattle Genetics	2012 - Hematologic Cancer Portal	\$28,000.00
Seattle Genetics	2012 - Annual Meeting Internet Stations	\$56,000.00
Seattle Genetics	2012 - ASCO iMeetings Mobile App	\$11,200.00
Sinplicity	In-Kind Donation	\$400.00
Symphogen A/S	2012 - Young Investigator Award	\$5,000.00
Teva Pharmaceuticals	2012 - Young Investigator Award	\$20,000.00

ASCO's Policy on Disclosure of Relationships with Companies

JOURNAL OF CLINICAL ONCOLOGY

ASCO SPECIAL ARTICLE

American Society of Clinical Oncology: Policy for Relationships With Companies

American Society of Clinical Oncology

Processed as a Rapid Communication manuscript. See accompanying article doi: 10.1200/JCO.2013.49.4997

From the American Society of Clinical Oncobgy, Abxandria, VA.

Published outre ahead of print at www.jco.org on April 22, 2013.

Author's disclosures of note stip look-

I. INTRODUCTION


The American Society of Clinical Oncology ("the Society") is dedicated to con quering cancer through

Code") is a set of principles that requires signatory societies to adopt policies for transparency and independence in transactions and activities involving for-profit entities that develop, produce, market, or

Home Disclosure

ASCO Form for Disclosure of Relationships with Companies

The purpose of this system is to provide ASCO audiences with information about certain relationships that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. The form should be updated when there is new information or at the time of any new ASCO activity. Review the detailed instructions prior to completing the form.



Can a Uniform System be Created?

Toward a Harmonized and Centralized Conflict of Interest Disclosure

Progress From an IOM Initiative

Allen S. Lichter, MD			health care providers, and physicians and re	
Ross McKinney, MD			should convene a broad-based process to standard content, a standard format, and stand	
		/ · ·	dures for disclosure of financial relationships	

Summary

- Medical professional societies have been active in creating transparent and trustworthy processes designed to maintain public trust.
- Disclosure of relationships and management of conflicts have been a key objective.
- Having a <u>uniform</u> disclosure system would be an important step forward.